| First Author | Atashrazm F | Year | 2021 |
| Journal | Oncogene | Volume | 40 |
| Issue | 25 | Pages | 4245-4262 |
| PubMed ID | 34099863 | Mgi Jnum | J:307139 |
| Mgi Id | MGI:6718698 | Doi | 10.1038/s41388-021-01813-6 |
| Citation | Atashrazm F, et al. (2021) The polarity protein PARD3 and cancer. Oncogene 40(25):4245-4262 |
| abstractText | Tissue disorganisation is one of the main hallmarks of cancer. Polarity proteins are responsible for the arrangement of cells within epithelial tissues through the asymmetric organisation of cellular components. Partition defective 3 (PARD3) is a master regulator of the Par polarity complex primarily due to its ability to form large complexes via its self-homologous binding domain. In addition to its role in polarity, PARD3 is a scaffolding protein that binds to intracellular signalling molecules, many of which are frequently deregulated in cancer. The role of PARD3 has been implicated in multiple solid cancers as either a tumour suppressor or promoter. This dual functionality is both physiologically and cell context dependent. In this review, we will discuss PARD3's role in tumourigenesis in both laboratory and clinical settings. We will also review several of the mechanisms underpinning PARD3's function including its association with intracellular signalling pathways and its role in the regulation of asymmetric cell division. |
